takeaways of dapa-hf: sglt2s for cvd
Published 4 years ago • 187 plays • Length 2:17Download video MP4
Download video MP3
Similar videos
-
8:28
sglt2 inhibitors in patients without diabetes at risk of hf
-
5:39
dr milton packer discusses the combined impact of emperor-reduced, dapa-hf
-
5:33
recent studies of sglt-2s in patients with hfref
-
3:48
quantifying potential impact of sglt2 inhibitors for hf
-
8:15
sglt2 inhibitors and heart failure
-
2:27
cardiovascular benefit with sglt2 inhibition
-
4:28
dapa-hf: substudy shows dapagliflozin reduces t2d risk in hf
-
5:59
implications of using sglt2 inhibitors with hfpef and hfref
-
5:18
dr javed butler on sglt-2 inhibitors' role in preventing hf
-
3:50
dr. mcmurray discusses the dapa-hf trial of dapagliflozin in systolic heart failure
-
2:53
dapagliflozin for heart failure: a pooled analysis of dapa-hf and deliver
-
3:35
hf 2022: deliver extends benefits of dapagliflozin to the full spectrum of pts with hf
-
6:57
how does dapagliflozin work? understanding sglt2 inhibitors.
-
11:50
sglt2 inhibitors in acute heart failure the earlier the better dictate ahf
-
3:08
dapa trial
-
6:57
hfa 2020: dapagliflozin and diuretic use in patients with hfref in dapa-hf — dr alice m jackson
-
0:34
nice guidelines on sglt2 inhibitors
-
6:06
esc 2019: empa-reg outcome - dr david fitchett
-
50:30
protocols for safe use of sglt2i and glp1ra in the hospital setting